# VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

> **NCT01581138** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 64 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** VX-222
- **DRUG:** telaprevir
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01581138
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-06
- **Final completion:** 2013-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581138, "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT01581138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*